93 related articles for article (PubMed ID: 29259349)
1. Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?
Bossi P; Siano M; Bergamini C; Cossu Rocca M; Sponghini AP; Giannoccaro M; Tonella L; Paoli A; Marchesi E; Perrone F; Pilotti S; Locati LD; Canevari S; Licitra L; De Cecco L
Dis Markers; 2017; 2017():6870614. PubMed ID: 29259349
[TBL] [Abstract][Full Text] [Related]
2. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
Bossi P; Bergamini C; Siano M; Cossu Rocca M; Sponghini AP; Favales F; Giannoccaro M; Marchesi E; Cortelazzi B; Perrone F; Pilotti S; Locati LD; Licitra L; Canevari S; De Cecco L
Clin Cancer Res; 2016 Aug; 22(15):3961-70. PubMed ID: 26920888
[TBL] [Abstract][Full Text] [Related]
3. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
4. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
6. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H
Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593
[TBL] [Abstract][Full Text] [Related]
7. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
8. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
9. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
10. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
11. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.
Siano M; Espeli V; Mach N; Bossi P; Licitra L; Ghielmini M; Frattini M; Canevari S; De Cecco L
Oral Oncol; 2018 Jul; 82():144-151. PubMed ID: 29909889
[TBL] [Abstract][Full Text] [Related]
12. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
[TBL] [Abstract][Full Text] [Related]
14. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.
da Costa AABA; Costa FD; Araújo DV; Camandaroba MPG; de Jesus VHF; Oliveira A; Alves ACF; Stecca C; Machado L; de Oliveira ACF; de Oliveira TB; Nicolau UR; de Lima VCC
Med Oncol; 2018 Nov; 36(1):8. PubMed ID: 30478503
[TBL] [Abstract][Full Text] [Related]
15. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.
Madoz-Gúrpide J; Zazo S; Chamizo C; Casado V; Caramés C; Gavín E; Cristóbal I; García-Foncillas J; Rojo F
J Transl Med; 2015 Aug; 13():282. PubMed ID: 26319934
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Licitra L; Störkel S; Kerr KM; Van Cutsem E; Pirker R; Hirsch FR; Vermorken JB; von Heydebreck A; Esser R; Celik I; Ciardiello F
Eur J Cancer; 2013 Apr; 49(6):1161-8. PubMed ID: 23265711
[TBL] [Abstract][Full Text] [Related]
18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
[TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.
Bouhaddou M; Lee RH; Li H; Bhola NE; O'Keefe RA; Naser M; Zhu TR; Nwachuku K; Duvvuri U; Olshen AB; Roy R; Hechmer A; Bolen J; Keysar SB; Jimeno A; Mills GB; Vandenberg S; Swaney DL; Johnson DE; Krogan NJ; Grandis JR
JCI Insight; 2021 Oct; 6(20):. PubMed ID: 34546978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]